Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes

PHASE3CompletedINTERVENTIONAL
Enrollment

1,034

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2009

Conditions
Breast Cancer
Interventions
DRUG

Cyclophosphamide, Epirubicin, Paclitaxel

4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d

DRUG

Epirubicin, Paclitaxel, Filgrastim

cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)

Trial Locations (1)

10365

Oskar-Ziethen-Krankenhaus, Berlin

All Listed Sponsors
lead

North Eastern German Society of Gynaecological Oncology

OTHER

NCT00668616 - Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes | Biotech Hunter | Biotech Hunter